Logo image of APEN

APOLLO ENDOSURGERY INC (APEN) Stock Fundamental Analysis

NASDAQ:APEN - Nasdaq - US03767D1081 - Common Stock - Currency: USD

10  +0.08 (+0.81%)

After market: 9.99 -0.01 (-0.1%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to APEN. APEN was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of APEN have multiple concerns. APEN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year APEN has reported negative net income.
In the past year APEN has reported a negative cash flow from operations.
In the past 5 years APEN always reported negative net income.
In the past 5 years APEN always reported negative operating cash flow.
APEN Yearly Net Income VS EBIT VS OCF VS FCFAPEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

APEN has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APEN Yearly ROA, ROE, ROICAPEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

1.3 Margins

APEN has a Gross Margin of 55.20%. This is comparable to the rest of the industry: APEN outperforms 52.58% of its industry peers.
In the last couple of years the Gross Margin of APEN has declined.
APEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y-2.23%
APEN Yearly Profit, Operating, Gross MarginsAPEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50

More info and screens

1

2. Health

2.1 Basic Checks

APEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
APEN has more shares outstanding than it did 1 year ago.
APEN has a worse debt/assets ratio than last year.
APEN Yearly Shares OutstandingAPEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
APEN Yearly Total Debt VS Total AssetsAPEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -0.16, we must say that APEN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.16, APEN is not doing good in the industry: 60.56% of the companies in the same industry are doing better.
APEN has a Debt/Equity ratio of 1.04. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.04, APEN is not doing good in the industry: 79.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Altman-Z -0.16
ROIC/WACCN/A
WACC10.2%
APEN Yearly LT Debt VS Equity VS FCFAPEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.35 indicates that APEN has no problem at all paying its short term obligations.
With a Current ratio value of 2.35, APEN is not doing good in the industry: 66.20% of the companies in the same industry are doing better.
A Quick Ratio of 1.89 indicates that APEN should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.89, APEN is not doing good in the industry: 60.56% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 1.89
APEN Yearly Current Assets VS Current LiabilitesAPEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

APEN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.99%.
APEN shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.01%.
The Revenue has been growing slightly by 3.63% on average over the past years.
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.21%
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y3.63%
Sales Q2Q%31.8%

3.2 Future

The Earnings Per Share is expected to grow by 11.79% on average over the next years. This is quite good.
The Revenue is expected to grow by 33.84% on average over the next years. This is a very strong growth
EPS Next Y13.1%
EPS Next 2Y11.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.29%
Revenue Next 2Y20.22%
Revenue Next 3Y33.84%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
APEN Yearly Revenue VS EstimatesAPEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
APEN Yearly EPS VS EstimatesAPEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

APEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APEN Price Earnings VS Forward Price EarningsAPEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APEN Per share dataAPEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.79%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APOLLO ENDOSURGERY INC

NASDAQ:APEN (4/3/2023, 8:15:00 PM)

After market: 9.99 -0.01 (-0.1%)

10

+0.08 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-30 2023-03-30/amc
Earnings (Next)05-01 2023-05-01
Inst Owners64.4%
Inst Owner Change-31.82%
Ins Owners25.67%
Ins Owner Change0%
Market Cap475.49M
Analysts76.36
Price Target10.2 (2%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-13.12%
Min EPS beat(2)-18.32%
Max EPS beat(2)-7.91%
EPS beat(4)0
Avg EPS beat(4)-11.05%
Min EPS beat(4)-18.32%
Max EPS beat(4)-4.68%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.43%
Min Revenue beat(2)5.11%
Max Revenue beat(2)5.74%
Revenue beat(4)4
Avg Revenue beat(4)4.43%
Min Revenue beat(4)3.3%
Max Revenue beat(4)5.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-13.04%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.19
P/FCF N/A
P/OCF N/A
P/B 14.59
P/tB 19.66
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.85
Fwd EYN/A
FCF(TTM)-0.72
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS1.62
BVpS0.69
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.2%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.92%
GM growth 5Y-2.23%
F-Score3
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 1.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 1.89
Altman-Z -0.16
F-Score3
WACC10.2%
ROIC/WACCN/A
Cap/Depr(3y)51.5%
Cap/Depr(5y)41.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.21%
EPS Next Y13.1%
EPS Next 2Y11.79%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)22.01%
Revenue growth 3Y14.87%
Revenue growth 5Y3.63%
Sales Q2Q%31.8%
Revenue Next Year18.29%
Revenue Next 2Y20.22%
Revenue Next 3Y33.84%
Revenue Next 5YN/A
EBIT growth 1Y-44.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-113.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-116.29%
OCF growth 3YN/A
OCF growth 5YN/A